We are live on ! Find out more
KZIA

Kazia Therapeutics

35 hedge funds and large institutions have $50.7M invested in Kazia Therapeutics in 2026 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 10 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,384% more call options, than puts

Call options by funds: $6.4M | Put options by funds: $431K

289% more capital invested

Capital invested by funds: $13M → $50.7M (+$37.7M)

240% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 5

150% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 4

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

52% more funds holding

Funds holding: 2335 (+12)

16.5% more ownership

Funds ownership: 15.35%31.85% (+17%)

Holders
35
Holders Change
+12
Holders Change %
+52.17%
% of All Funds
0.42%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.02%
New
17
Increased
10
Reduced
4
Closed
5
Calls
$6.4M
Puts
$431K
Net Calls
+$5.97M
Net Calls Change
+$5.96M

KZIA Hedge Fund Activity: Q2 2026 in Review

35 of the 8,340 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q2 2026, worth a combined $50.7M — up 289% from $13M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new KZIA positions and 5 closed out — a net gain of 12 holders — while 10 added to existing stakes and 4 trimmed.

The largest buyer was Boxer Capital Management, opening a new position worth an estimated $6.82M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $1.44M sold.

  • 35 institutional investors held Kazia Therapeutics (KZIA) as of Q2 2026, up from 23 in Q1 2026.
  • Funds reported $50.7M of Kazia Therapeutics stock for Q2 2026, up 289% quarter-over-quarter.
  • 17 funds opened new Kazia Therapeutics positions in Q2 2026 and 5 closed out, a net change of +12 holders.
  • The largest Kazia Therapeutics buyer in Q2 2026 was Boxer Capital Management, an estimated $6.82M added.
  • The largest Kazia Therapeutics seller in Q2 2026 was Balyasny Asset Management, an estimated $1.44M sold.

Based on aggregated 13F filings for Q2 2026.